Stay updated with breaking news from Nasdaq Cdtx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday. Several other equities analysts have also recently weighed in on CDTX. TheStreet cut shares of Cidara Therapeutics from a “c” rating to […]
Legacy Wealth Asset Management LLC bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Free Report) in the 2nd quarter, HoldingsChannel reports. The fund bought 30,000 shares of the biotechnology company’s stock, valued at approximately $34,000. Other institutional investors and hedge funds also recently made changes to their positions in the company. […]
Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,320,000 shares, a decrease of 12.0% from the September 30th total of 1,500,000 shares. Based on an average daily volume of 513,000 shares, […]
Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) saw a significant decrease in short interest in October. As of October 15th, there was short interest totalling 1,320,000 shares, a decrease of 12.0% from the September 30th total of 1,500,000 shares. Based on an average trading volume of 513,000 shares, the short-interest ratio is presently 2.6 […]
The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and...